Cell transplantation models / T47D
Breast carcinoma (ER+/PR+)
Hormone-positive breast line; s.c. and orthotopic models often need estrogen. Do not copy Price 1990 / 231 doses.
SKU: MC-h209 · Disease models · In-vitro spheroid
ER+/PR+ T47D flank s.c. CDX usually needs exogenous estrogen for endocrine pharmacology. This SOP uses Lee: 2×10⁶ flank s.c.; 60-day estrogen pellet 7 days pre—μL/gel not stated. Lee’s other arm 1×10⁷ is for established-tumor therapy, not the default inoculum. Not fat-pad orthotopic. Do not copy MDA-MB-231’s 2×10⁶ / 100 μL or Price 1990.
Open full protocol →
Hind / #4 fat-pad ER+ T47D typically needs exogenous estrogen. This SOP uses Holen: 5×10⁵ in 20 μL (50% Matrigel:50% PBS), left and right hind fat pads; E2 pellet 3 days pre. Matsunaga contrast: 5×10⁶ in 100 μL 50% Matrigel, #4 pad, E2 0.5 mg / 60-day 1 day pre. Not Price 1990, and not 231’s 2×10⁶ / 100 μL.
Open full protocol →
Red [Non-metastatic] = local tumorigenesis, not a distant-met endpoint; [Weak metastasis evidence] = poorly supported for parental line—exploratory/negative-control use.